Novo Drops NovoSeven Stroke Program Following Phase III Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
Danish firm says studies of the coagulation factor in cardiac surgery and trauma will move ahead as planned.
You may also be interested in...
Novo Nordisk Will Halt Small Molecule R&D To Focus On Therapeutic Proteins
Small molecule projects in development will be out-licensed, including the Phase I glucokinase activator NN9101.
NovoSeven Wins Expanded Indication For Acquired Hemophilia
Novo Nordisk’s coagulation Factor VIIa is the first recombinant therapy approved for treatment of acquired hemophilia.
Novo Nordisk Pulls Unlucky NovoSeven Application In EU
Novo Nordisk will resubmit the application for its factor VIIa product for a supplemental intracerebral hemorrhage indication.